Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BigKahuna, BooDog, KarinCA, noretreat, TOB, starbuxsux
Search This Board:
Last Post: 5/3/2015 12:34:48 PM - Followers: 580 - Board type: Free - Posts Today: 20

Cellceutix Corporation (CTIX) 
 

 

http://cellceutix.com/
 

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
CIK:  0001355250
 
Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial in Miami, FL. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.

 

Management:   http://cellceutix.com/team/
The above link is kept updated.
http://www.zoominfo.com/p/Daniel-Jorgensen/1064701588
 

 
Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/
 

 
Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:
EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 
 

 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
Wiki
CTIX News: Current Report Filing (8-k) 04/27/2015 07:34:19 AM
CTIX News: Securities Registration (section 12(b)) (8-a12b) 04/27/2015 06:28:28 AM
CTIX News: Cellceutix closes $30M stock purchase agreement 04/01/2015 08:59:20 AM
CTIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 03/31/2015 04:19:17 PM
CTIX News: Independent Research Initiates Analyst Coverage on Inventergy Global, Inc. (NASDAQ: INVT) with $1.20 Price Target 03/12/2015 08:00:00 AM
PostSubject
#99743  Sticky Note CTIX NASDAQ UPLISTING RALLY WATCH TOB 04/28/15 03:25:02 PM
#97761  Sticky Note There was actually quite a bit packed into BigKahuna 04/14/15 02:18:26 PM
#95145  Sticky Note $CTIX Lead drug info, News, SEC filings, FDA KarinCA 03/21/15 12:39:45 PM
#92697  Sticky Note upcoming catalysts slcimmuno 02/26/15 09:18:08 AM
#87958  Sticky Note Cellceutix Reports Spleen Lesion 'Disappears' in Patient With starbuxsux 01/20/15 08:25:55 AM
#74575  Sticky Note Cellceutix Announces Positive Top-Line Data From Phase 2b TOB 10/23/14 11:59:10 AM
#100347   Yeah, and when that one goes bankrupt, there Drano 05/03/15 12:34:48 PM
#100346   hers mine, wheres theirs cascott 05/03/15 12:04:24 PM
#100345   If we do get added to the Russell John B 05/03/15 11:54:37 AM
#100344   link please on corneal penetration...my research found suggesting cascott 05/03/15 11:53:02 AM
#100343   Please provide a link to your research as thefamilyman 05/03/15 11:44:39 AM
#100342   link please on corneal penetration...my research found suggesting cascott 05/03/15 11:35:10 AM
#100341   Just FYI - The guy who replaced Patrick thefamilyman 05/03/15 11:15:24 AM
#100340   Revenue NOT required... GA*T & NN*C are thefamilyman 05/03/15 11:07:42 AM
#100339   It isn't. loanranger 05/03/15 11:07:22 AM
#100338   NNV* has no revenue, but is in the John B 05/03/15 11:05:19 AM
#100337   Russell 2000 Index vip1999 05/03/15 10:43:10 AM
#100336   Perhaps the prospect of Brilacidin's imminent approval is thefamilyman 05/03/15 08:20:01 AM
#100335   Predicting cancer years ahead with a blood test? CallMeCrazy 05/03/15 07:01:27 AM
#100334   Excellent post. Thank you for sharing your knowledge! John B 05/03/15 05:44:57 AM
#100333   Sox is correct about the three half-lifes.. gives 1hb 05/03/15 03:10:31 AM
#100332   Haha I don't post often, but I'll do sox040713 05/03/15 02:16:28 AM
#100331   Both Ortavancin and Dalbavancin have a very long sox040713 05/03/15 02:13:48 AM
#100330   Thanks for that. So 1000 of the 100000 BaartP 05/03/15 02:02:27 AM
#100329   I think the FDA's main objective of the sox040713 05/03/15 01:28:14 AM
#100328   Thanks! CTIX has a lot going on lately, sox040713 05/03/15 01:23:54 AM
#100327   ...or drop another 50 cents... Looping 05/02/15 11:31:21 PM
#100326   I don't think the excerpted paragraph negates my CallMeCrazy 05/02/15 11:31:08 PM
#100325   Milestones, certainly. But I think we get the frrol 05/02/15 11:21:32 PM
#100324   Seems they updated the In Vitro Brilacidin antibacterial TOB 05/02/15 10:43:40 PM
#100323   A17 do you see any differences btw B scottsmith 05/02/15 10:37:14 PM
#100322   Sounds very promising. Thank you very much for FarmaZutical 05/02/15 10:29:13 PM
#100321   No problem F1 :) I think that P JPsooner 05/02/15 10:01:35 PM
#100320   What I am saying is - with competitors Amatuer17 05/02/15 09:54:20 PM
#100319   Not strictly true; slcimmuno provided an article excerpt frrol 05/02/15 09:10:21 PM
#100318   thank you for both of your answers eom gov govorchin 05/02/15 08:51:13 PM
#100317   Great summary. My take on B and eye CallMeCrazy 05/02/15 08:10:18 PM
#100316   Thank you. Still wonder why it isn't being frrol 05/02/15 08:08:54 PM
#100315   No chance of FDA fast track approval at frrol 05/02/15 08:05:42 PM
#100314   Good Slide deck out of UK on getting slcimmuno 05/02/15 07:49:50 PM
#100313   It has an "elimination half-life of 0.7 hours frrol 05/02/15 07:48:11 PM
#100312   Yes single dose = a huge cost saver From slcimmuno 05/02/15 07:38:47 PM
#100311   Lol, sorry JP I though you said where F1ash 05/02/15 07:38:02 PM
#100310   Actually, I like WHAT you did there. rearden 05/02/15 07:36:22 PM
#100309   Well it's some "distraction". See the Cubist and frrol 05/02/15 07:35:56 PM
#100308   Right. I have no idea where Dr. J JPsooner 05/02/15 07:21:22 PM
#100307   Only a couple of ABX can work as frrol 05/02/15 07:20:32 PM
#100306   Thanks! I like you did there. rearden 05/02/15 07:13:51 PM
#100305   Disclosing a buyout offer (and partnership offers, licensing frrol 05/02/15 07:10:02 PM
#100304   One would think, but not referencing Cellceutix -- slcimmuno 05/02/15 07:10:02 PM
#100303   i stand corrected. eom gov govorchin 05/02/15 07:07:14 PM
#100301   Great stuff farrell! Besides the resistance problem, fluroquinolone sox040713 05/02/15 06:49:39 PM
#100300   SLC, I'm pretty sure Leo is aware of sox040713 05/02/15 06:36:57 PM
#100299   And when the co conspirators finally end their etradeedge 05/02/15 06:35:11 PM
#100298   Gov, it was nine doses in three cycles. sox040713 05/02/15 06:26:24 PM
#100297   With my 1000th post, here's the potential catalysts sox040713 05/02/15 06:22:20 PM
PostSubject